This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Reunion Neuroscience Valuation

Is REUN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of REUN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate REUN's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate REUN's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for REUN?

Other financial metrics that can be useful for relative valuation.

REUN key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDAn/a
PEG Ration/a

Price to Book Ratio vs Peers

How does REUN's PB Ratio compare to its peers?

The above table shows the PB ratio for REUN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPBEstimated GrowthMarket Cap
Peer Average1.2x
WLLW Willow Biosciences
2.2xn/aCA$12.4m
AEZS Aeterna Zentaris
0.4x18.0%CA$12.9m
MPH Medicure
0.8xn/aCA$16.6m
IBT IBEX Technologies
1.5xn/aCA$20.2m
REUN Reunion Neuroscience
0.8x-14.0%CA$16.6m

Price-To-Book vs Peers: REUN is good value based on its Price-To-Book Ratio (0.8x) compared to the peer average (1.2x).


Price to Earnings Ratio vs Industry

How does REUN's PE Ratio compare vs other companies in the CA Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a43.0%
n/an/an/a
No. of CompaniesPB048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a43.0%
n/an/an/a
No more companies

Price-To-Book vs Industry: REUN is good value based on its Price-To-Book Ratio (0.8x) compared to the Canadian Biotechs industry average (1.5x)


Price to Book Ratio vs Fair Ratio

What is REUN's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

REUN PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio0.8x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate REUN's Price-To-Book Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies

Price7D1Y
Mkt CapP/EGrowth
Price7D1Y
Mkt CapP/EGrowth
Price7D1Y
Mkt CapP/EGrowth
Price7D1Y
Mkt CapP/EGrowth